- Home
- NCPL vs WINT Comparison
NCPL vs WINT Comparison
Compare NCPL & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- WINT
- Stock Information
- Founded
- NCPL 1984
- WINT 1992
- Country
- NCPL United States
- WINT United States
- Employees
- NCPL N/A
- WINT N/A
- Industry
- NCPL Investment Managers
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCPL Finance
- WINT Health Care
- Exchange
- NCPL Nasdaq
- WINT Nasdaq
- Market Cap
- NCPL 4.3M
- WINT 3.6M
- IPO Year
- NCPL N/A
- WINT 1995
- Fundamental
- Price
- NCPL $2.70
- WINT $0.75
- Analyst Decision
- NCPL
- WINT Hold
- Analyst Count
- NCPL 0
- WINT 1
- Target Price
- NCPL N/A
- WINT $350.00
- AVG Volume (30 Days)
- NCPL 166.3K
- WINT 216.5K
- Earning Date
- NCPL 07-28-2025
- WINT 05-16-2025
- Dividend Yield
- NCPL N/A
- WINT N/A
- EPS Growth
- NCPL N/A
- WINT N/A
- EPS
- NCPL N/A
- WINT N/A
- Revenue
- NCPL $812,612.00
- WINT N/A
- Revenue This Year
- NCPL N/A
- WINT N/A
- Revenue Next Year
- NCPL $101.16
- WINT N/A
- P/E Ratio
- NCPL N/A
- WINT N/A
- Revenue Growth
- NCPL N/A
- WINT N/A
- 52 Week Low
- NCPL $1.41
- WINT $0.67
- 52 Week High
- NCPL $11.90
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- NCPL 76.49
- WINT 31.91
- Support Level
- NCPL $1.75
- WINT $0.73
- Resistance Level
- NCPL $2.19
- WINT $0.85
- Average True Range (ATR)
- NCPL 0.21
- WINT 0.06
- MACD
- NCPL 0.07
- WINT 0.03
- Stochastic Oscillator
- NCPL 84.85
- WINT 27.67
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.